Pegfilgrastim compared with filgrastim in patients with acute myeloid leukemia after chemotherapy
Phase 2
- Conditions
- eutropenia.Other disorders of white blood cells
- Registration Number
- IRCT20151020024625N8
- Lead Sponsor
- Semnan University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 58
Inclusion Criteria
Patients who went to remission after induction chemotherapy.
Exclusion Criteria
Non remission
Sepsis during or after chemotherapy
History of hypersensitivity reactions to E. coli-derived proteins and other drugs
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method eutrophil count. Timepoint: Daily< up to 21 days after intervention. Method of measurement: Complete blood cell count and peripheral blood smear.
- Secondary Outcome Measures
Name Time Method